SEED Innovations Ltd (AIM:SEED, OTC:FFRIF) has welcomed the interim results from its portfolio company Little Green Pharma Ltd (ASX:LGP).
Revenue for the ASX-listed medicinal cannabis business jumped 130% from the year-earlier period to A$9.2mln (£5.2mln) in the six months to end September 2022.
Its losses narrowed to A$7.8mln from A$8.6mln even as research and development spending jumped by about 63% to A$4.4mln.
AIM-quoted SEED holds a 2.8% stake in Little Green Pharma.